In a phase I trial the toxicity and immunomodulatory effects of combined treatment with intravenous (i.v.)bispecific monoclonal antibody BIS-1 and subcutaneous (s.c.)interleukin 2 (IL-2) was studied in renal cell cancer patients. The gene discussed is IL2; the disease is renal cell adenocarcinoma.